Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 23;23(19):11212.
doi: 10.3390/ijms231911212.

Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis

Sevindzh Kletukhina  1 , Guzel Mutallapova  1 , Angelina Titova  2 , Marina Gomzikova  1
Affiliations
Review

Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis

Sevindzh Kletukhina et al. Int J Mol Sci. .

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic disease that leads to disability and death within 5 years of diagnosis. Pulmonary fibrosis is a disease with a multifactorial etiology. The concept of aberrant regeneration of the pulmonary epithelium reveals the pathogenesis of IPF, according to which repeated damage and death of alveolar epithelial cells is the main mechanism leading to the development of progressive IPF. Cell death provokes the migration, proliferation and activation of fibroblasts, which overproduce extracellular matrix, resulting in fibrotic deformity of the lung tissue. Mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) are promising therapies for pulmonary fibrosis. MSCs, and EVs derived from MSCs, modulate the activity of immune cells, inhibit the expression of profibrotic genes, reduce collagen deposition and promote the repair of damaged lung tissue. This review considers the molecular mechanisms of the development of IPF and the multifaceted role of MSCs in the therapy of IPF. Currently, EVs-MSCs are regarded as a promising cell-free therapy tool, so in this review we discuss the results available to date of the use of EVs-MSCs for lung tissue repair.

Keywords: extracellular vesicles; lung damage; mesenchymal stem cells; mesenchymal stem cells derived extracellular vesicles; pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathways of myofibroblast formation during IPF. The figure shows the different cell types that respond to stimulation by profibrotic growth factors (TGF-β, CTGF), cytokines (IL-1, IL-13, IL-4, IL-6, TNF-α), signaling pathways (Wnt/β-catenin, Notch1/PDGFRβ/ROCK1), chemokines (CXCL12, SLC, CCL1), specific EMT transcription factors (Snail2, ZEB1, TWIST, p62/SQSTM1), adhesion molecules (ICAM-1,VCAM-1, FAK and CDH-11), hyperoxia, exposure to endothelin-1 and nicotine, overexpression of α-SMA, COL1α1 and fibronectin, upregulation of SMAD2, SMAD3, Sp1 and c-Myc differentiated into myofibroblasts [65,70,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102] (Created with BioRender.com, accessed on 4 July 2022).
Figure 2
Figure 2
Schematic representation of the lung tissue damage therapy mechanism in IPF by means of mesenchymal stem cell-derived extracellular vesicles. The footnotes in the figure indicate: the composition of EVs-MSCs—proteins (PRKCZ, TIMP-1, TIMP-2, BMP-7), transcription factors (NF-κβ p50, NF-κβ p65), miRNAs (miR-182-5p, miR-214-3p, miR-29b-3p, miR-23a-3p) and therapeutic effect of EVs-MSCs (Created with BioRender.com, accessed on 22 September 2022).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ley B., Collard H.R., King T.E., Jr. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI. - DOI - PubMed
    1. Gross T.J., Hunninghake G.W. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2001;345:517–525. doi: 10.1056/NEJMra003200. - DOI - PubMed
    1. Yamashita M., Yamauchi K., Chiba R., Iwama N., Date F., Shibata N., Kumagai H., Risteli J., Sato S., Takahashi T., et al. The definition of fibrogenic processes in fibroblastic foci of idiopathic pulmonary fibrosis based on morphometric quantification of extracellular matrices. Hum. Pathol. 2009;40:1278–1287. doi: 10.1016/j.humpath.2009.01.014. - DOI - PubMed
    1. Shochet G.E., Brook E., Israeli-Shani L., Edelstein E., Shitrit D. Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF) Respir. Res. 2017;18:122. doi: 10.1186/s12931-017-0606-x. - DOI - PMC - PubMed
    1. Pan L.-H., Yamauchi K., Uzuki M., Nakanishi T., Takigawa M., Inoue H., Sawai T. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. 2001;17:1220–1227. doi: 10.1183/09031936.01.00074101. - DOI - PubMed

MeSH terms

LinkOut - more resources